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introduction: In current literature, the immune-inflammatory theory of atherosclerosis is widely discussed. 
The role of how heat shock proteins 60 (HSP60) lead to the development of the atheromatous plaque is espe-
cially underlined. The aim of the study is to estimate the influence of three hormonal protocols on behavior of 
antibodies against HSP60. It determines the state of endothelium in postmenopausal women.
material and methods: The study was carried out on 90 women between 2007 and 2012. All the women 
were in their menopausal age (51 ± 3 years), from the south region of Poland, with a follicle stimulating hormone 
(FSH) level above 25 mIU/ml, and with menopausal symptoms disturbing their normal daily activity. The study 
was done for a period of 6 months. Three groups of 30 randomized patients were formed. In the first group 
we used transdermal estrogen therapy in a 37.5 μg/24 h dose combined with a 10 mg dose of dydrogester-
one. In the second group we applied transdermal estrogen therapy in a 50 μg/24 h dose with 2.5 mg of oral 
medroxyprogesterone. In both these groups, gestagens were administered continuously. In the third group, we 
prescribed continuous, oral, low-dose combined estrogen-gestagen therapy with 1 mg of ethinyl estradiol and 
0.5 mg of norethisterone acetate. The control group consisted of 30 volunteers who were also from the south 
region of Poland, in good health, with menopausal symptoms, no menstrual period for the last 12 months, se-
lected considering their age and weight, with an FSH level above 25 mIU/ml and with normal levels of thyroid 
stimulating hormone (TSH) and prolactin. All patients treated and in the control group were seronegative to 
Chlamydia pneumonia for the entire duration of the study. In the analysis conducted, nonparametric tests were 
used (Mann-Whitney U test, Wilcoxon test, Kruskal-Wallis test – ANOVA).
results: After 6 months of hormonal therapy, we found that all schemes of treatment promote a significant 
reduction in antibodies against HSP60 in all treated groups vs. the control group.
Conclusions: All of the investigated estrogen protocols have a favorable impact on the blood level of HSP60 
antibodies in early postmenopausal women who have no cardiovascular risk factors. It triggers a better condi-
tion of endothelium.
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Introduction
There are many inflammatory-immune markers 
which play an important prognostic role in modern 
medicine, particularly in peri- and postmenopausal 
time. An especially interesting issue is the possible im-
pact of postmenopausal lack of sex hormone produc-
tion and replacement therapy on a  vessel’s immune-
inflammatory condition [1]. Increased levels of those 
markers are signs of a  chronic immune-inflammatory 
process in atherosclerosis, arterial hypertension, obe-
sity, diabetes mellitus, and others [2].
In current literature, the immune-inflammatory the-
ory of atherosclerosis is widely discussed. Heat shock 
proteins 60 (HSP60) and their role in the development 
of the atheromatous plaque are especially underlined. 
They are intracellular molecules and signaling intercel-
lular proteins, and have the ability to initiate cytokine 
secretion and expression of cells’ adhesion molecules. 
The production of heat shock proteins (also called 
‘stress proteins’) is stimulated by a  sudden increase 
in intracellular temperature, and by any other kind of 
cellular stress such as oxidative stress, viral infection, 
exposure to some chemical substances (e.g. ethanol), 
cytokines, and heavy metal ions; which all lead to the 
dysfunction of endothelial cells. The presence of human 
native HSP60 on a  vessel’s endothelial surface might 
lead to an autoimmune reaction, depending on anti-
body or complement cytotoxic reactions [2].
The exposure of the host’s HSP60 on the endothe-
lial cells and macrophage surfaces causes these cells to 
be damaged by anti-HSP60 immunoglobulins [2].
Reduction in the level of antibodies against heat shock proteins 60 during 
different hormonal protocols in postmenopausal women
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Antibodies of HSP60 are present in small concentra-
tion in the blood of healthy individuals; the physiologi-
cal reaction remains unclear [3].
It has been proven that monoclonal antibodies specif-
ic for HSP60 and antibodies against the HSP60 – a fam-
ily isolated from human serum have a cytotoxic impact 
on the endothelium [2-6]. These studies demonstrate 
that antibodies against HSP60 might play a role in vessel 
damage and atherosclerosis etiopathogenesis [2-6].
HSP60 expression might also be secondary to the 
inflammatory process when the cytokine expression 
in the endothelium and in leukocytes leads to a HSP 
expression in the vessel wall. HSP60 were once consid-
ered as intracellular molecules, but these proteins can 
be released from live cells to the extracellular space 
through a  mechanism which is still unclear [2-4]. Ex-
tracellular HSP60 are signaling molecules and influence 
several inflammatory reactions.
These proteins might have an impact on atheroscle-
rosis development acting as target autoantigens for re-
active T cells that damage their own HSP60 [2].
Having knowledge about the beneficial influence 
of estrogens on healthy endothelial cells as well as the 
inflammatory theory of atherosclerosis, we carried out 
the study aimed to illustrate the influence of three dif-
ferent forms of hormonal protocols on the behavior of 
antibodies against HSP60 in healthy postmenopausal 
women with climacteric symptoms, and compared 
these results to the control group.
Material and methods
Series description, inclusion criteria
The study was carried out on 90 women hospital-
ized or treated in the outpatient clinic at the Endocrino-
logical Gynecology Department, Jagiellonian University 
between 2007 and 2012. All the patients were in men-
opausal age (51 ± 3 years), from the south region of 
Poland, with follicle stimulating hormone (FSH) levels 
above 25 mIU/ml, with menopausal symptoms disturb-
ing their normal daily activity [7]; they all fulfilled cri-
teria for hormonal therapy specified by the Standards 
of Polish Gynecological Society. The study was done 
for a period of 6 months, during which there were no 
lifestyle changes, only observation of whether or not 
quality of life improved (measured by the Green Scale). 
No other drugs due to chronic illnesses were taken. 
Three groups of 30 randomized patients were formed. 
The study was a double-blind randomized trial, the pa-
tients were selected to a proper group by the computer. 
None of the doctors were involved in the study. In the 
first group we gave transdermal estrogen therapy in 
a 37.5 μg/24 h dose combined with a 10 mg dose of dy-
drogesterone taken orally. In the second group we pre-
scribed transdermal estrogen therapy in a 50 μg/24 h 
dose with 2.5 mg of oral medroxyprogesterone. In both 
these groups gestagens were administered continu-
ously. In the third group we applied a continuous, oral, 
low-dose combined estrogen–gestagen therapy with 
1 mg of ethinyl estradiol and 0.5 mg of norethisterone 
acetate.
Group I  (n = 30): 37.5 μg/24 h of transdermal 
17β-estradiol, in combination with 10 mg of dydro-
gesterone (commercial products: Oesclim 37.5 and 
Duphaston – tablets), abbreviation: 37.5+D.
Group II (n = 30): 50 μg/24 h of transdermal 
17β-estradiol, in combination with 2.5 mg of medroxy-
progesterone (commercial products: Oesclim 50 and 
Provera 5 mg – half a tablet), abbreviation: 50+MPA.
Group III (n = 30): 1 mg of 17β-estradiol in combina-
tion with 0.5 mg norethisterone acetate as a continu-
ous oral therapy (commercial product: Activelle), abbre-
viation: Activelle.
Selection of these therapy schemes was suitable. 
Cho’s in-vivo data have shown that oral gestagen 
therapy has the ability to relax smooth muscle cells by 
slackening calcium channels, independent of dose [8]. 
Thirty volunteers also from the south region of Poland, 
in a  good health condition, without chronic diseases, 
with menopausal symptoms, with no menstrual period 
in the last 12 months, formed the control group. All pa-
tients treated and in the control group were seronega-
tive to Chlamydia pneumonia for the entire duration of 
the experiment.
Exclusion criteria
In our study, candidates with the following medical 
records were excluded: taking hormonal menopausal 
therapy at the time of evaluation (medical history), suf-
fering from unexplained uterine bleeding (medical his-
tory), with a history of endometriosis (medical history, 
transvaginal ultrasound [USG]), with uterine myoma(s) 
(medical history, transvaginal USG), with arterial hyper-
tension (daily blood pressure records – systolic pressure 
less than 140 mm Hg and diastolic pressure less than 
90 mm Hg were accepted as normal), with coronary ar-
tery disease (echocardiogram, electrocardiography, car-
diac stress test), with diabetes mellitus (oral glucose tol-
erance test with 75 g of glucose), with an active or chronic 
inflammatory process (medical history, C-reactive pro-
tein > 10 ng/dl, white blood cells [WBC] > 10 000/mm3), 
with autoimmune diseases (medical history), with a liv-
er dysfunction (liver function blood tests), with kidney 
diseases (sodium, potassium, creatinine or blood urea 
level beyond the norm), with any neoplasms in their 
medical history, who have undergone thrombophlebi-
tis or venous thromboembolism (medical history), with 
cholelithiasis, but not after cholecystectomy (medical 
history), with seizures in the course of a disease includ-
ing epilepsy (medical history), with migraine (medical 
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history), overweight or obese (body mass index – BMI 
– score equal to or more than 25 and with the waist-hip 
ratio equal to or more than 0.78).
Smoking and alcohol consumption were taken into 
consideration in medical history as well.
The following tests were performed for each patient:
•	 detailed medical history considering arterial hyper-
tension, diabetes mellitus, smoking, inflammatory 
conditions, liver and kidney diseases, neoplasms, and 
present pharmacological treatment,
•	 physical examination with hemodynamic evaluation,
•	 blood pressure measurement,
•	 anthropometric measurements including body weight 
and height (BMI), and waist and hipline (waist-hip 
ratio – WHR),
•	 biochemical tests including morphology, hormone 
levels (FSH, E2 – estradiol, TSH – thyroid stimulating 
hormone, PRL – prolactin), total cholesterol, LDL-cho-
lesterol, HDL-cholesterol, and triglycerides,
•	 antibodies against HSP60 – ELISA immunoenzymatic 
method,
•	 IgA antibodies against Chlamydia pneumonia.
All patients were informed about the medical study 
and joined it voluntarily, giving their written consent. 
Our study has been approved by the Ethics Committee 
of the Jagiellonian University.
Serum samples were collected and stored at –70oC. 
All samples were tested at the same time (May 2011). All 
hormones were determined by immunoassay “ECLIA”. 
Total cholesterol and high density lipoprotein (HDL) 
levels were determined by enzymatic and colorimetric 
methods. Plasma triglyceride levels were determined 
with an enzymatic commercial kit (Abbot). Low den-
sity lipoprotein (LDL) levels were estimated according 
to the Friedewald equation. Antibodies against HSP60 
were determined by an immunoenzymatic method 
using a  commercial kit (Stressgen Biotechnologies). 
The normal level for HSP60 antibodies: 7.81-250 ng/ml, 
and sensitivity 3 ng/ml. IgA antibodies against Chla-
mydia pneumoniae were also examined using the im-
munoenzymatic method (ANI Labsystem, Finland).
Statistical analysis
In the analysis conducted, nonparametric tests 
were used.
Analyzed parameters in treated groups were com-
pared using the Mann-Whitney U  test. By using the 
Wilcoxon test, the obtained results in examination 1 
(before the treatment) and examination 2 (six months 
after the hormonal therapy was initiated) in each study 
group were compared. The differences in outcomes of 
investigations in resolved materials were confronted 
using Kruskal-Wallis test (ANOVA), and in cases where 
significant changes were shown between groups, 
a  multiple comparison test was applied to find those 
differences. The Pearson’s linear correlation coefficient 
was used to estimate correlations between analyzed 
parameters and between changes in these factors. 
p < 0.05 was statistically significant. Lack of statistical 
significance was indicated by the abbreviation NS (non-
statistically significant).
Results were shown as a table and figure. Calcula-
tions and analysis were made using STATISTICA 7.1.
Results
Characteristics of the study groups
Women in our study groups do not differ signifi-
cantly regarding age, anthropometric measurements, 
blood levels of hormones (estradiol, FSH, PRL, and 
TSH), total cholesterol, LDL and HDL cholesterol and 
triglycerides. There was no statistically significant dif-
ference in the blood level of anti-HSP60 antibodies in 
the study groups. The results for the 90 participants in 
the study and control groups are shown in Table I and 
Figure 1.
Tab. i.  Levels of antibodies against heat shock proteins 60 (HSP60) in examination 1 (before therapy) and examination 2 (six 
months after starting hormonal therapy) in examined groups
Group antibodies HSP60 p
exam. x Sd min me max
Activelle 1 279 365 204 350 40 881 145 838 789 986 0.01
2 148 152 111 914 41 562 68 340 468 195
50+MPA 1 122 616 87 398 27 719 93 076 265 091 0.05
2 80 149 80 038 22 954 104 990 404 881
37.5+D 1 150 094 200 356 32 587 75 716 690 338 0.003
2 100 658 167 648 27 946 80 822 684 462
Control 1 92 849 83 744 21 592 65 731 260 552 0.002
2 165 484 62 534 26 811 71 290 282 791
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The results demonstrated that after 6 months, 
hormonal therapy promoted a significant reduction in 
antibodies against HSP60 in all treated groups vs. the 
control group, where we observed an increase in the ex-
amined antibodies (group I p = 0.003, group II p = 0.05, 
group III p = 0.01, vs. control group p = 0.002, using 
paired Wilcoxon test) (Table I). 
Kruskal-Wallis test (ANOVA) (Fig. 1) showed statisti-
cally significant differences (p = 0.001) between chang-
es in the control group and changes in all study groups. 
To localize these differences, a multiple comparison test 
was performed, which did not detect any statistically 
significant changes. Clinically, regardless of the dose 
of estrogen, way of its administration, kind of oral ge-
stagen, they all have a  positive impact on antibodies 
against HSP60.
Discussion
Heat shock proteins belong to a group of conserva-
tive proteins which are produced by almost every or-
ganism. These proteins are produced in the human 
body, and in microorganisms such as: Chlamydia pneu-
moniae, and mycobacterium. In physiological condi-
tions of the body, HSP are present mainly in mitochon-
dria, where they take part in the stabilization of internal 
proteins.
An interesting observation was presented by Veres 
et al. and Burian et al. who noted that although there is 
a 75% homology between mycobacterial HSP65 and hu-
man HSP60, levels of their antibodies are only weakly cor-
related. The immunological response to human heat shock 
proteins should therefore be further explored [9, 10].
Our original study is one of the few papers inves-
tigating the influence of different forms of hormonal 
therapy on the behavior of antibodies against HSP60 
in healthy postmenopausal women. The results pre-
sented are different from observations by Uint et al. 
[11] who showed an increased level of antibodies 
against HSP60 vs. the control group in women with 
a mean age of 62, using conjugated estrogens in 0.625 
mg doses with medroxyprogesterone acetate in a 2.5 
mg dose, administered continuously. It is worth un-
derlining that the women in the examined population 
were different, which probably had an influence on the 
results.
In our study we proved that there is a beneficial effect 
on HSP60 after hormonal treatment comparing to the 
control group. However, we would like to emphasize that 
there is no statistically significant difference between the 
discussed groups based on the dose and way of adminis-
tration of estrogens, or the type of gestagen given.
In our own data, a  linear correlation was shown 
between changes of antibodies against HSP60 and 
changes of BMI (r = 0.3330, p = 0.036). An inversely 
proportional correlation between changes of antibodies 
against HSP60 and changes of the estradiol level was 
also detected (r = –0.2653, p = 0.048).
In a paper written by Yu et al., the positive effects 
of estradiol (E2) on the cardiac function are mediated 
via β-receptor of estradiol and its receptor induces up-
regulation of heat shock proteins. It plays a significant 
role in the E2-mediated cardioprotection after trauma 
haemorrhage in Sprague-Dawley rats [12].
Conclusions
In conclusion, any of the investigated estrogen 
protocols has a favorable impact on the blood level of 
HSP60 antibodies in postmenopausal women with no 
cardiovascular risk factors.
The essential element in the prevention of endotheli-
al dysfunction is to search for new biochemical or immu-
nological markers with a prognostic value; HSP60 being 
one of them. This heat shock protein is a marker of the 
formation and progression of the endothelial dysfunc-
tion, but its clinical role warrants further investigations.
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fig. 1.  The comparison of changes in levels of antibodies aga-
inst heat shock proteins 60 (HSP60) between examined groups 
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